A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A
Cells · 19.06.2025 · 14 (12) · 929
DOI: 10.3390/cells14120929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 19.06.2025. Verfasst von Noha M Abdelrazik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK. Hauptthemen laut MEDLINE: Endosomal Sorting Complexes Required for Transport, Colorectal Neoplasms, Drug Resistance, Neoplasm, Oxaliplatin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education of Egypt, Ministry of Higher Education of the Arab Republic of Egypt.
Abstract (Originalsprache)
Drug resistance is still one of the main challenges for the treatment of colorectal cancer (CRC). Whilst some resistance mechanisms are well known, from the static therapy success rate, clearly, still much is undiscovered. Intracellular transport mechanisms have attracted attention as having a possible role in drug resistance, and here, the Endosomal Sorting Complex Required for Transport (ESCRT) protein family is studied as a source of drug resistance modulation using human CRC cell lines and clinical material. From an initial screening of ESCRT proteins in a panel of 10 CRC wild-type cell lines using immunoblotting, Vacuolar Protein Sorting-Associated Protein A4 (VPS4A) was identified as being consistently highly expressed, and it was selected for further investigation. Immunohistopathological evaluation in a small panel of CRC patient samples demonstrated high expression in the tumor epithelium compared to normal intestinal epithelium. The knockdown of VPS4A resulted in enhanced sensitivity of cells to oxaliplatin, and it was subsequently seen that oxaliplatin-resistant sublines had significantly higher VPS4A expression than their wild-type variants. In addition, it was demonstrated that a small molecule inhibitor of VPS4A, aloperine, could interact synergistically with oxaliplatin to enhance its sensitivity in an oxaliplatin-resistant cell line. We hypothesize from initial RNA sequencing analysis that the mechanism of action of VPS4A modulation is through depleting levels of the drug efflux transporter MRP2 in the cell, preventing oxaliplatin egress and increasing cell exposure to the drug. The evidence presented here thus indicates that ESCRT machinery, specifically VPS4A, may act as a modulator of oxaliplatin resistance in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK.
- Faculty of Pharmacy, University of Sadat City, El Sadat City 32897, Egypt.
- Department of Medical Oncology, Bradford Royal Infirmary, Bradford Teaching Hospitals NHS Foundation Trust, Bradford BD9 6RJ, UK.
ORCID-Profile: Sriharsha Kantamneni, Steven D Shnyder
Förderung
- Ministry of Higher Education of Egypt
- Ministry of Higher Education of the Arab Republic of Egypt
Zitieren
APA
Abdelrazik, N. M., Patel, A., Conn, A., Sutton, C. W., Kantamneni, S., & Shnyder, S. D. (2025). A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A. Cells, 14(12), 929. https://doi.org/10.3390/cells14120929
Vancouver
Abdelrazik NM, Patel A, Conn A, Sutton CW, Kantamneni S, Shnyder SD. A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A. Cells. 2025;14(12):929. doi:10.3390/cells14120929
BibTeX
@article{Abdelrazik2025,
author = {Abdelrazik, Noha M and Patel, Anjana and Conn, Andrew and Sutton, Christopher W and Kantamneni, Sriharsha and Shnyder, Steven D},
title = {A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A},
journal = {Cells},
year = {2025},
volume = {14},
number = {12},
pages = {929},
doi = {10.3390/cells14120929}
}
EUVIMED